FI971420A0 - Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä - Google Patents

Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä

Info

Publication number
FI971420A0
FI971420A0 FI971420A FI971420A FI971420A0 FI 971420 A0 FI971420 A0 FI 971420A0 FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 A0 FI971420 A0 FI 971420A0
Authority
FI
Finland
Prior art keywords
kgf
diabetes mellitus
treating diabetes
mammals
pharmaceutical compositions
Prior art date
Application number
FI971420A
Other languages
English (en)
Swedish (sv)
Other versions
FI971420A (fi
Inventor
Sharon Lea Aukerman
Glenn Frencis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI971420A publication Critical patent/FI971420A/fi
Publication of FI971420A0 publication Critical patent/FI971420A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI971420A 1994-10-13 1997-04-04 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä FI971420A0 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number Publication Date
FI971420A FI971420A (fi) 1997-04-04
FI971420A0 true FI971420A0 (fi) 1997-04-04

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971420A FI971420A0 (fi) 1994-10-13 1997-04-04 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Country Status (23)

Country Link
EP (2) EP0785948B1 (fi)
JP (2) JP4216329B2 (fi)
KR (1) KR100278597B1 (fi)
CN (1) CN1168678A (fi)
AT (2) ATE237633T1 (fi)
AU (1) AU3707795A (fi)
BG (2) BG101392A (fi)
BR (2) BR9509269A (fi)
CA (2) CA2202075C (fi)
CZ (3) CZ98197A3 (fi)
DE (2) DE69530403T2 (fi)
DK (2) DK0804479T3 (fi)
EE (2) EE9700225A (fi)
ES (2) ES2273338T3 (fi)
FI (2) FI971420A0 (fi)
HU (2) HUT78050A (fi)
NO (2) NO318761B1 (fi)
NZ (2) NZ505502A (fi)
PL (2) PL320484A1 (fi)
PT (2) PT804479E (fi)
SI (2) SI0804479T1 (fi)
SK (2) SK43197A3 (fi)
WO (2) WO1996011949A2 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647732B2 (en) 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
CN1129955A (zh) 1993-06-29 1996-08-28 奇龙公司 截短的生物活性更高的角质形成细胞生长因子
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
DK0785949T3 (da) * 1994-10-13 2003-08-18 Amgen Inc Fremgangsmåde til oprensning af keratinocytvækstfaktorer
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
WO1996034017A1 (en) * 1995-04-27 1996-10-31 Coöperatie Suiker Unie U.A. Inulin derivatives
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU727678C (en) * 1996-10-15 2005-05-12 Biovitrum Ab (Publ) Keratinocyte growth factor-2 products
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
JP2001526239A (ja) 1997-12-22 2001-12-18 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
US20040063634A1 (en) * 2001-01-19 2004-04-01 Carr Francis J. Modified kertinocyte growth factor (kgf) with reduced immunogenicity
CA2457781A1 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
PL1827483T3 (pl) 2004-12-15 2014-12-31 Swedish Orphan Biovitrum Ab Publ Formulacje terapeutyczne czynnika wzrostu keratynocytów
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
WO1990000877A1 (en) * 1988-07-27 1990-02-08 Marjan International Pty Ltd Carpet stretcher
AU647732B2 (en) * 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
JP3578761B2 (ja) * 1993-03-26 2004-10-20 アムジエン・インコーポレーテツド 表皮ケラチン細胞成長因子の治療目的での使用
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
CN1129955A (zh) * 1993-06-29 1996-08-28 奇龙公司 截短的生物活性更高的角质形成细胞生长因子
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
HUT78050A (hu) 1999-07-28
HU226168B1 (en) 2008-05-28
NO971566L (no) 1997-04-14
CZ297328B6 (cs) 2006-11-15
ES2273338T3 (es) 2007-05-01
CZ105097A3 (cs) 1998-10-14
EP0785948B1 (en) 2003-04-16
AU3707795A (en) 1996-05-06
DK0804479T3 (da) 2007-01-29
BG101392A (en) 1997-10-31
DE69535264T2 (de) 2007-02-01
FI971420A (fi) 1997-04-04
WO1996011949A2 (en) 1996-04-25
NZ505502A (en) 2005-01-28
CZ297329B6 (cs) 2006-11-15
EP0785948A1 (en) 1997-07-30
PT804479E (pt) 2007-02-28
ATE342278T1 (de) 2006-11-15
SI0804479T1 (sl) 2006-12-31
CZ98197A3 (cs) 1998-11-11
DE69535264D1 (de) 2006-11-23
NO971568D0 (no) 1997-04-04
JPH10507080A (ja) 1998-07-14
BG101408A (en) 1997-12-30
SK45597A3 (en) 1999-02-11
NO318761B1 (no) 2005-05-02
CN1168678A (zh) 1997-12-24
ES2196082T3 (es) 2003-12-16
FI120040B (fi) 2009-06-15
DE69530403D1 (de) 2003-05-22
SI0785948T1 (en) 2003-08-31
CA2202075C (en) 2003-12-09
DE69530403T2 (de) 2003-10-30
EE9700225A (et) 1998-02-16
EP0804479A1 (en) 1997-11-05
BR9509269A (pt) 1997-12-23
PL182888B1 (pl) 2002-03-29
ATE237633T1 (de) 2003-05-15
JP4216329B2 (ja) 2009-01-28
BR9509329A (pt) 1997-10-14
NO971566D0 (no) 1997-04-04
FI971536A0 (fi) 1997-04-11
NO971568L (no) 1997-06-12
JP4426646B2 (ja) 2010-03-03
PT785948E (pt) 2003-09-30
EE9700081A (et) 1997-10-15
CA2201940A1 (en) 1996-04-25
JPH10507193A (ja) 1998-07-14
BG63167B1 (bg) 2001-05-31
SK43197A3 (en) 1999-03-12
EP0804479B1 (en) 2006-10-11
EE03975B1 (et) 2003-02-17
FI971536A (fi) 1997-06-09
NZ335109A (en) 2000-08-25
HUT78058A (hu) 1999-07-28
PL320484A1 (en) 1997-09-29
PL319784A1 (en) 1997-08-18
AU3708395A (en) 1996-05-06
CA2202075A1 (en) 1996-04-25
CA2201940C (en) 2009-05-12
WO1996011950A1 (en) 1996-04-25
WO1996011949A3 (en) 1996-12-12
SK284534B6 (sk) 2005-06-02
KR100278597B1 (ko) 2001-01-15
AU681546B2 (en) 1997-08-28
DK0785948T3 (da) 2003-08-04

Similar Documents

Publication Publication Date Title
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
FR2491334B1 (fi)
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
GB9410639D0 (en) Method of improving fertilization
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
SE9400524D0 (sv) Energipreparat
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
ATE315583T1 (de) Analoge des thymosin alpha 1
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці